Literature DB >> 10511027

Utility values and diabetic retinopathy.

M M Brown1, G C Brown, S Sharma, G Shah.   

Abstract

PURPOSE: To ascertain the utility values associated with diabetic retinopathy and varying degrees of visual loss.
METHODS: One hundred consecutive patients with diabetic retinopathy and best-corrected visual acuity decreased to 20/40 or worse in at least one eye occurring primarily as a result of diabetic retinopathy were evaluated in a cross-sectional study. Utility values were ascertained in five groups using both the time trade-off and standard gamble methods: group 1 (best-corrected visual acuity in the better eye of 20/20 to 20/25), group 2 (best-corrected visual acuity in the better eye of 20/30 to 20/50), group 3 (best-corrected visual acuity in the better eye of 20/60 to 20/100), group 4 (best-corrected visual acuity in the better eye of 20/200 to 20/400), and group 5 (best-corrected visual acuity in the better eye of counting fingers to hand motions).
RESULTS: The mean utility value for the diabetic retinopathy group as a whole was 0.77 (SD = 0.21; 95% confidence interval [CI], 0.73 to 0.81) with the time trade-off method and 0.88 (SD = 0.20; 95% CI, 0.84 to 0.92) with the standard gamble method. Employing the time trade-off method correlated with the best-corrected visual acuity in the better eye, the mean utility results were as follows: group 1 = 0.85 (95% CI, 0.75 to 0.95), group 2 = 0.78 (CI, 0.72 to 0.84), group 3 = 0.78 (CI, 0.67 to 0.89), group 4 = 0.64 (CI, 0.53 to 0.75), and group 5 = 0.59 (CI, 0.23 to 0.95). Thus, patients in group 1 (best-corrected visual acuity of 20/20 to 20/25 in the better eye) were willing to trade a mean of 15% of their remaining years of life in return for perfect vision in each eye, whereas those in group 5 (best-corrected visual acuity of counting fingers to hand motions in the better eye) were willing to trade a mean of 41% of their remaining years in return for perfect vision in each eye. There was no significant difference in mean utility values between patients who had decreased visual acuity from diabetic retinopathy for 1 year or less compared with those with decreased acuity for more than 1 year. There was also no significant difference in mean utility values between those with a 12th grade education or less compared with those with more than a 12th grade education.
CONCLUSION: Visual loss occurring secondary to diabetic retinopathy is associated with a substantial decrease in patient utility value (and quality of life). The utility value is directly dependent on the degree of visual loss associated with the disease. The length of time of visual loss and amount of formal education do not appear to affect the utility value.

Entities:  

Mesh:

Year:  1999        PMID: 10511027     DOI: 10.1016/s0002-9394(99)00146-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  48 in total

1.  The reproducibility of ophthalmic utility values.

Authors:  G C Brown; M M Brown; S Sharma; G Beauchamp; H Hollands
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

Authors:  M M Brown; G C Brown; S Sharma; A F Smith; J Landy
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

3.  Vision and quality-of-life.

Authors:  G C Brown
Journal:  Trans Am Ophthalmol Soc       Date:  1999

4.  Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study.

Authors:  Kashif Mazhar; Rohit Varma; Farzana Choudhury; Roberta McKean-Cowdin; Corina J Shtir; Stanley P Azen
Journal:  Ophthalmology       Date:  2010-10-29       Impact factor: 12.079

5.  Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration.

Authors:  P A Aspinall; A R Hill; B Dhillon; A M Armbrecht; P Nelson; C Lumsden; E Farini-Hudson; R Brice; A Vickers; P Buchholz
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

6.  Quality of life and systemic comorbidities in patients with ophthalmic disease.

Authors:  Melissa M Brown; Gary C Brown; Sanjay Sharma; Hussein Hollands; Jennifer Landy
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

7.  Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.

Authors:  Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki
Journal:  Qual Life Res       Date:  2011-08-04       Impact factor: 4.147

8.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis.

Authors:  David Maberley; Hugh Walker; Anita Koushik; Alan Cruess
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

10.  Variation in treatment preferences and care goals among older patients with diabetes and their physicians.

Authors:  Marshall H Chin; Melinda L Drum; Lei Jin; Morgan E Shook; Elbert S Huang; David O Meltzer
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.